Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | EGFR | P00533 | 1/20 | 0.56 |
| ▸ | ROS1 | P08922 | 1/20 | 0.56 |
| ▸ | ALK | Q9UM73 | 1/20 | 0.56 |
| ▸ | MAPK3 | P27361 | 12/20 | 0.53 |
| ▸ | MAPK1 | P28482 | 3/20 | 0.51 |
| ▸ | ACVRL1 | P37023 | 1/20 | 0.50 |
| ▸ | ABL1 | P00519 | 2/20 | 0.46 |
| ▸ | MAP3K7 | O43318 | 1/20 | 0.44 |
| ▸ | ULK1 | O75385 | 1/20 | 0.44 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3333893 | 0.88 | KMT2A (0.46) | EGFRROS1ALKMAPK3ACVRL1 | |
| SCHEMBL3335414 | 0.87 | KMT2A (0.51) | EGFRROS1ALKMAPK3ACVRL1 | |
| SCHEMBL13300591 | 0.85 | EGFR (0.64) | EGFRROS1ALKMAPK3MAPK1 | |
| SCHEMBL13300654 | 0.84 | EGFR (0.68) | EGFRROS1ALKMAPK3MAPK1 | |
| SCHEMBL13300648 | 0.82 | EGFR (0.63) | EGFRROS1ALKMAPK3MAPK1 | |
| SCHEMBL25004486 | 0.82 | ROS1 (0.52) | EGFRROS1ALKMAPK3MAPK1 | |
| SCHEMBL29904740 | 0.82 | ROS1 (0.52) | EGFRROS1ALKMAPK3MAPK1 | |
| SCHEMBL13300621 | 0.81 | MAPK9 (0.65) | EGFRROS1ALKMAPK3MAPK1 | |
| SCHEMBL13300617 | 0.81 | EGFR (0.62) | EGFRROS1ALKMAPK3MAPK1 | |
| SCHEMBL13300615 | 0.81 | EGFR (0.71) | EGFRROS1ALKMAPK3MAPK1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 11 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20100144732-A1 | PYRIMIDINE KINASE INHIBITORS | GENENTECH, INC. | 2010-06-10 | — | — | US | disclosed |
| US-20100144732-A1 | PYRIMIDINE KINASE INHIBITORS | GENENTECH, INC. | 2010-06-10 | — | — | US | disclosed |
| US-20100144732-A1 | PYRIMIDINE KINASE INHIBITORS | GENENTECH, INC. | 2010-06-10 | — | — | US | disclosed |
| EP-2099771-A1 | PYRIMIDINE KINASE INHIBITORS | Genentech, Inc. (US) | 2009-09-16 | — | — | EP | disclosed |
| US-20080318989-A1 | Pyrimidine Kinase Inhibitors | GENENTECH, INC. | 2008-12-25 | — | — | US | disclosed |
| US-20080318989-A1 | Pyrimidine Kinase Inhibitors | GENENTECH, INC. | 2008-12-25 | — | — | US | disclosed |
| US-20080318989-A1 | Pyrimidine Kinase Inhibitors | GENENTECH, INC. | 2008-12-25 | — | — | US | disclosed |
| EP-1968950-A1 | PYRIMIDINE KINASE INHIBITORS | Genentech, Inc. (US) | 2008-09-17 | — | — | EP | disclosed |
| WO-2008079719-A1 | PYRIMIDINE KINASE INHIBITORS | GENENTECH, INC. (US) | 2008-07-03 | — | — | WO | disclosed |
| WO-2007120339-A1 | PYRIMIDINE KINASE INHIBITORS | GENENTECH, INC. (US) | 2007-10-25 | — | — | WO | disclosed |
| WO-2007120339-A1 | PYRIMIDINE KINASE INHIBITORS | GENENTECH, INC. (US) | 2007-10-25 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080318989-A1 | Pyrimidine Kinase Inhibitors | DCK, DTYMK, TK1 | EGFR 762/4885ROS1 274/4885ALK 465/4885 |
| US-20100144732-A1 | PYRIMIDINE KINASE INHIBITORS | DTYMK, DCK, TYMP | EGFR 1008/4885ROS1 257/4885ALK 415/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.